Lxr modulators

Abstract

Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

We claim: 
     
         1 . A compound, isotope, or pharmaceutically acceptable salt thereof, which is 2-(1-(3′-fluoro-4′-(hydroxymethyl)-5′-(methylsulfonyl)biphenyl-4-yl)-2-(2-(2-fluorophenyl)propan-2-yl)-1H-imidazol-4-yl)propan-2-ol. 
     
     
         2 . A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof of  claim 1 , and one or more pharmaceutically acceptable carriers. 
     
     
         3 . A method of treating a disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof of  claim 1 , wherein the disease or disorder is atherosclerosis, insulin resistance, osteoarthritis, stroke, hyperglycemia, dyslipidemia, psoriasis, age and UV exposure-related skin wrinkling, diabetes, cancer, Alzheimer's disease, inflammation, immunological disorders, lipid disorders, obesity, macular degeneration, conditions characterized by a perturbed epidermal barrier function, conditions of disturbed differentiation or excess proliferation of the epidermis or mucous membrane, or cardiovascular disorders. 
     
     
         4 . The method of  claim 3  wherein the disease or disorder is atherosclerosis, diabetes, Alzheimer's disease or dyslipidemia. 
     
     
         5 . The method of  claim 3  wherein the disease or disorder is atherosclerosis. 
     
     
         6 . The method of  claim 3  wherein the disease or disorder is diabetes. 
     
     
         7 . The method of  claim 3  wherein the disease or disorder is Alzheimer's disease.